Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) (NCT06686394)
HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Who can join: Review the eligibility criteria below.
Location: University of Colorado Anschutz Medical Campus ( Site 0057) — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- University of Colorado Anschutz Medical Campus ( Site 0057) — Aurora, Colorado
- Dana-Farber Cancer Institute ( Site 0050) — Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey ( Site 0052) — New Brunswick, New Jersey
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053) — Greenville, South Carolina
- Inova Schar Cancer Institute ( Site 0051) — Fairfax, Virginia
- Kingston General Hospital ( Site 0061) — Kingston, Ontario
- Princess Margaret Cancer Centre ( Site 0001) — Toronto, Ontario
- Centre Hospitalier de l'Université de Montréal ( Site 0004) — Montreal, Quebec
- Jewish General Hospital ( Site 0003) — Montreal, Quebec
- Rambam Health Care Campus ( Site 0011) — Haifa,
- Rabin Medical Center ( Site 0012) — Petah Tikva,
- Sheba Medical Center ( Site 0010) — Ramat Gan,
- Nagoya City University Hospital ( Site 0020) — Nagoya, Aichi-ken
- Seoul National University Hospital ( Site 0030) — Seoul,
- Asan Medical Center ( Site 0031) — Seoul,
- University College London Hospital ( Site 0041) — London, Camden
- The Beatson West of Scotland Cancer Centre ( Site 0043) — Glasgow, Glasgow City
- St Bartholomew s Hospital ( Site 0040) — London, London, City of
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.